肝素结合蛋白在重症患者中的临床应用  

Clinical application of heparin-binding protein in severe patients

作　　者：冯立伟 王婕莹 王洪亮[1] 郑俊波[1] Feng Liwei;Wang Jieying;Wang Hongliang;Zheng Junbo(Critical Care Medicine Department,the Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China)

机构地区：[1]哈尔滨医科大学附属第二医院重症医学科,黑龙江哈尔滨150086

出　　处：《中国急救医学》2023年第7期579-584,共6页Chinese Journal of Critical Care Medicine

基　　金：国家重点研发计划(2021YFC2501800);哈尔滨医科大学附属第二医院横向课题(070500020243[2020])。

摘　　要：重症患者常存在不同程度的器官功能障碍,尽管其病死率因过去几年各种生命支持手段迅速发展而改善,但早期准确识别仍存在一定困难。肝素结合蛋白(heparin binding protein,HBP)作为一种新近出现的生物标志物,在许多重症疾病的病理生理中起到重要作用。大量研究表明,HBP可早期、迅速、准确对重症患者进行病情评估及预后判断。本文将对HBP在不同病因导致的重症患者临床应用的最新研究进展进行综述。Severe patients often have various degrees of organ dysfunction.Although the mortality has been improved due to the rapid development of multilple life support methods in the past few years,early and accurate identification is still challenging.As a novel biomarker,heparin-binding protein(HBP)plays an important role in the pathophysiology of many severe diseases.Numerous studies have shown that HBP is an early,rapid and accurate marker for severity assessment and prognosis prediction in severe patients.This article reviews the latest research progress of HBP clinical application in severe patients caused by different reasons.

关 键 词：肝素结合蛋白(HBP) 重症疾病 生物标志物 脓毒症 急性细菌性脑膜炎 急性呼吸窘迫综合征 急性肾损伤 急性胰腺炎 

分 类 号：R459.7[医药卫生—急诊医学]